Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma japonicum | Integrin beta-PS precursor, putative | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Schistosoma japonicum | Integrin beta-3 precursor, putative | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Brugia malayi | Integrin beta pat-3 precursor | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Echinococcus multilocularis | integrin beta 2 | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Schistosoma japonicum | ko:K06464 integrin beta 2, putative | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Echinococcus granulosus | integrin beta 2 | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Loa Loa (eye worm) | integrin beta-2 | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Schistosoma mansoni | integrin beta subunit | Get druggable targets OG5_127959 | All targets in OG5_127959 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium leprae | Probable dihydroorotate dehydrogenase PyrD | 0.3206 | 1 | 0.5 |
Trypanosoma cruzi | dihydroorotate dehydrogenase (fumarate), putative | 0.3206 | 1 | 1 |
Mycobacterium ulcerans | dihydroorotate dehydrogenase 2 | 0.3206 | 1 | 0.5 |
Trypanosoma cruzi | dihydroorotate dehydrogenase, putative | 0.3206 | 1 | 1 |
Trichomonas vaginalis | dihydroorotate dehydrogenase, putative | 0.1252 | 0.345 | 0.5 |
Plasmodium falciparum | dihydroorotate dehydrogenase | 0.3206 | 1 | 0.5 |
Echinococcus granulosus | dihydropyrimidine dehydrogenase NADP | 0.1252 | 0.345 | 1 |
Schistosoma mansoni | dihydroorotate dehydrogenase | 0.3206 | 1 | 1 |
Entamoeba histolytica | dihydropyrimidine dehydrogenase, putative | 0.1252 | 0.345 | 0.5 |
Trichomonas vaginalis | dihydropyrimidine dehydrogenase, putative | 0.1252 | 0.345 | 0.5 |
Toxoplasma gondii | dihydroorotate dehydrogenase reveal, putative | 0.3206 | 1 | 0.5 |
Trypanosoma brucei | dihydroorotate dehydrogenase (fumarate) | 0.3206 | 1 | 0.5 |
Brugia malayi | Zinc finger, C2H2 type family protein | 0.1252 | 0.345 | 0.3089 |
Mycobacterium tuberculosis | Probable dihydroorotate dehydrogenase PyrD | 0.3206 | 1 | 0.5 |
Trichomonas vaginalis | dihydroorotate dehydrogenase, putative | 0.1252 | 0.345 | 0.5 |
Trypanosoma cruzi | dihydroorotate dehydrogenase, putative | 0.3206 | 1 | 1 |
Trichomonas vaginalis | dihydroorotate dehydrogenase, putative | 0.1252 | 0.345 | 0.5 |
Leishmania major | dihydroorotate dehydrogenase | 0.3206 | 1 | 0.5 |
Echinococcus granulosus | dihydropyrimidine dehydrogenase NADP | 0.1252 | 0.345 | 1 |
Echinococcus multilocularis | dihydropyrimidine dehydrogenase (NADP+) | 0.1252 | 0.345 | 1 |
Brugia malayi | Dihydroorotate dehydrogenase, mitochondrial precursor, putative | 0.3206 | 1 | 1 |
Loa Loa (eye worm) | integrin beta-2 | 0.0378 | 0.0521 | 0.5 |
Trichomonas vaginalis | dihydroorotate dehydrogenase, putative | 0.1252 | 0.345 | 0.5 |
Echinococcus multilocularis | dihydropyrimidine dehydrogenase (NADP+) | 0.1252 | 0.345 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydroorotate dehydrogenase 2 | 0.3206 | 1 | 0.5 |
Trichomonas vaginalis | dihydroorotate dehydrogenase, putative | 0.1252 | 0.345 | 0.5 |
Plasmodium vivax | dihydroorotate dehydrogenase, mitochondrial precursor, putative | 0.3206 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 30 nM | Displacement of Eu-labeled VCAM-1 from human VLA alpha4 beta1 expressed in CHO-K1 cells after 60 mins by time-resolved fluorometric analysis | ChEMBL. | 22261021 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.